Ep. 210 Personalizing ADT Across the Prostate Cancer Spectrum with Dr. Rana McKay

900.565 - 923.123 Dr. Rana McKay

And are you actually impacting their survival in any way by giving them the two or four weeks of biclutamide? So I think, you know, not to say that there's been a movement away, but I think we are seeing less utilization of the first generation antiandrogens in the clinic because of the fact that we have these next generation agents and many individuals are getting such agents.